Form 4: Acrivon Therapeutics Executive Acquires Stock Options

Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reports acquisition of stock options.

Summary

• Erick Gamelin, the Chief Development Officer of Acrivon Therapeutics, Inc. acquired stock options on March 1, 2025.
• The transaction involved the acquisition of 78,078 stock options with an exercise price of $5.31.
• These options vest over time, with 25% vesting on March 1, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
• Following the transaction, Gamelin directly owns 78,078 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a standard executive compensation practice that aligns interests with shareholders.

Positives

• The acquisition of stock options by a key executive aligns their interests with the company's long-term success.
• The vesting schedule incentivizes continued service and commitment from the Chief Development Officer.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule described is typical, designed to align executive incentives with long-term company performance.
• Comparable companies such as Relay Therapeutics, Black Diamond Therapeutics, and Blueprint Medicines also utilize stock options as part of their executive compensation.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating that the Chief Development Officer is incentivized to contribute to the company's success.
• Employees may see this as a standard practice for executive compensation.

Key Dates